Beatriz Cuevas Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Researcher
faculty
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Beatriz Cuevas's research focuses on the clinical outcomes and treatment of myeloproliferative neoplasms (MPNs) and related hematological disorders. Her work has investigated the impact of COVID-19 on patients with MPNs, including mortality rates and specific risks associated with conditions like essential thrombocythemia. Cuevas has also examined the safety and efficacy of targeted therapies, such as asciminib and ruxolitinib, in real-world clinical practice for patients with chronic myeloid leukemia (CML) and polycythemia vera. Her research extends to the application of machine learning in improving risk stratification for myelofibrosis, utilizing data from patient registries. Cuevas holds an h-index of 17 with 94 total publications and 908 total citations.
Metrics
- h-index: 17
- Publications: 94
- Citations: 908
Selected Publications
-
Pharmacogenetic Biomarkers of Ibrutinib Response and Toxicity in Chronic Lymphocytic Leukemia: Insights from an Observational Study (2025)
-
Impact of Atrial Fibrillation on Patients with Myeloproliferative Neoplasms (2024)
-
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia (2024)
-
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis (2024)
-
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia (2024)
-
Author Correction: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (2024)
-
Integrating AIPSS‐MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis (2024)
-
The prognostic impact of non‐driver gene mutations and variant allele frequency in primary myelofibrosis (2024)
-
DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study (2024)
-
Clinical and Molecular Characterization of Triple-Negative Essential Thrombocythemia: Data from the Prospective Spanish Registry of Essential Thrombocythemia (2023)
-
DNMT3A/TET2/ASXL1 mutations are an age-independent thrombotic risk factor in polycythemia vera patients: an observational study (2023)
-
Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia (2023)
-
Bortezomib Pharmacogenetic Biomarkers for the Treatment of Multiple Myeloma: Review and Future Perspectives (2023)
-
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors (2023)
-
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis (2022)
Similar Researchers
Based on overlapping research topics